Hannah Marie Gilligan, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 6 | 2022 | 4116 | 0.410 |
Why?
|
| BK Virus | 2 | 2021 | 136 | 0.370 |
Why?
|
| Polyomavirus Infections | 2 | 2021 | 198 | 0.340 |
Why?
|
| Tumor Virus Infections | 2 | 2021 | 453 | 0.320 |
Why?
|
| Hepatorenal Syndrome | 1 | 2017 | 60 | 0.160 |
Why?
|
| Living Donors | 1 | 2021 | 569 | 0.150 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 1996 | 255 | 0.130 |
Why?
|
| Cytoplasmic Granules | 1 | 1996 | 627 | 0.130 |
Why?
|
| Vascular Diseases | 1 | 2022 | 1154 | 0.130 |
Why?
|
| Tissue and Organ Procurement | 1 | 2021 | 850 | 0.120 |
Why?
|
| Antilymphocyte Serum | 1 | 2014 | 520 | 0.120 |
Why?
|
| Organ Transplantation | 1 | 2022 | 1071 | 0.120 |
Why?
|
| Hepatitis C, Chronic | 1 | 2020 | 1002 | 0.110 |
Why?
|
| Withholding Treatment | 1 | 2014 | 580 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2020 | 1493 | 0.100 |
Why?
|
| Antiviral Agents | 2 | 2020 | 2768 | 0.090 |
Why?
|
| Immunophenotyping | 1 | 2014 | 1908 | 0.090 |
Why?
|
| Steroids | 1 | 2014 | 880 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2017 | 1723 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 2559 | 0.080 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 1721 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2017 | 2022 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 1896 | 0.070 |
Why?
|
| Graft Rejection | 2 | 2018 | 4408 | 0.070 |
Why?
|
| Neutrophils | 1 | 1996 | 3867 | 0.060 |
Why?
|
| Apoptosis | 2 | 1996 | 10085 | 0.060 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2004 | 302 | 0.060 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2004 | 851 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2020 | 15053 | 0.040 |
Why?
|
| New England | 1 | 2020 | 1021 | 0.040 |
Why?
|
| Microscopy, Immunoelectron | 1 | 1996 | 337 | 0.040 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 1996 | 65 | 0.040 |
Why?
|
| Antibody Affinity | 1 | 1996 | 260 | 0.040 |
Why?
|
| Comorbidity | 2 | 2021 | 10339 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 1996 | 1170 | 0.030 |
Why?
|
| Antibodies | 1 | 2022 | 2431 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2022 | 4831 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2017 | 709 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1996 | 2881 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2020 | 1309 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2018 | 1470 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2014 | 350 | 0.030 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2004 | 2100 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2014 | 717 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2018 | 2502 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2020 | 2147 | 0.020 |
Why?
|
| Health Surveys | 1 | 2020 | 3994 | 0.020 |
Why?
|
| Macrophages | 1 | 2004 | 5784 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1996 | 1976 | 0.020 |
Why?
|
| Glycoproteins | 1 | 1996 | 2309 | 0.020 |
Why?
|
| Rabbits | 1 | 2014 | 5163 | 0.020 |
Why?
|
| T-Lymphocytes | 2 | 2014 | 10362 | 0.020 |
Why?
|
| Humans | 10 | 2022 | 708843 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1996 | 3892 | 0.020 |
Why?
|
| Biopsy | 1 | 2018 | 6766 | 0.020 |
Why?
|
| Cell Survival | 1 | 1996 | 6156 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 1996 | 6127 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1996 | 4169 | 0.020 |
Why?
|
| Health Personnel | 1 | 2018 | 2983 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2004 | 163 | 0.020 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2004 | 169 | 0.020 |
Why?
|
| Massachusetts | 1 | 2017 | 8712 | 0.020 |
Why?
|
| Health Status | 1 | 2017 | 4015 | 0.020 |
Why?
|
| Time Factors | 2 | 2017 | 41038 | 0.020 |
Why?
|
| Kidney | 1 | 2018 | 6888 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2004 | 17218 | 0.010 |
Why?
|
| Incidence | 1 | 2020 | 20320 | 0.010 |
Why?
|
| Risk | 1 | 2014 | 9641 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2021 | 71483 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 5235 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 11239 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 2 | 2004 | 6684 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2014 | 7994 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7487 | 0.010 |
Why?
|
| Integrins | 1 | 2004 | 830 | 0.010 |
Why?
|
| Middle Aged | 3 | 2021 | 213752 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2004 | 1221 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2004 | 1144 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2004 | 3318 | 0.010 |
Why?
|
| beta 2-Glycoprotein I | 1 | 1996 | 26 | 0.010 |
Why?
|
| Anions | 1 | 1996 | 136 | 0.010 |
Why?
|
| Female | 4 | 2021 | 375205 | 0.010 |
Why?
|
| Actins | 1 | 2004 | 2191 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 3093 | 0.010 |
Why?
|
| Adsorption | 1 | 1996 | 214 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 1996 | 486 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 3936 | 0.010 |
Why?
|
| Phospholipids | 1 | 1996 | 813 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1996 | 1151 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1996 | 1858 | 0.010 |
Why?
|
| Thymus Gland | 1 | 1996 | 1328 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2017 | 61932 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 69553 | 0.010 |
Why?
|
| Animals | 3 | 2014 | 170486 | 0.010 |
Why?
|
| Male | 2 | 2017 | 349524 | 0.010 |
Why?
|
| Phenotype | 1 | 2004 | 16306 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2004 | 22989 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 12447 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 2004 | 18375 | 0.000 |
Why?
|
| Mice | 2 | 2004 | 80876 | 0.000 |
Why?
|